Navigation Links
Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results

BEIJING, Aug. 15, 2011 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTCBB: LTUS) ("Lotus" or the "Company"), a profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), today announced its financial results for the quarter ended June 30, 2011. Summary financial data is provided below:

Second Quarter Financial Highlights

  • Revenues for the three months ended June 30, 2011 decreased by 1.1% year-over-year to $18.7 million, down from $18.9 million in the second quarter of 2010
  • Wholesale revenues were $14.6 million, or 78% of total revenues
  • Retail revenues were $4.1 million, or 22% of total revenues

  • Gross profit for the second quarter was $4.9 million, a decrease of 50.1% compared to $9.8 million in the second quarter of 2010. Gross margin was 26.1% and 51.8% for the three months ended June 30, 2011 and 2010, respectively

  • Net income for the quarter decreased 71.9% to $1.8 million, compared to $6.3 million in the second quarter of 2010

  • Earnings per diluted share were $0.06 for the quarter, compared with diluted EPS of $0.24 achieved in the same period a year ago

  • Mr. Zhongyi Liu, Chairman and CEO of Lotus, stated, "Our 2011 second quarter results, especially those of the wholesale segment, were negatively impacted by changes in the competitive landscape and increases in labor costs. Retail sales continue to deliver solid results with 19.2% growth in revenue versus the same period in 2010. The increase in the retail segment was driven primarily by our Over-the-Counter division's sales. Construction of our Beijing facility continues to progress, and we anticipate additional capacity for growth and significant efficiency improvements once we move into the new building by the end of the year."

    Mr. Liu continued, "We plan to focus our capital expenditures in the foreseeable future on the completion of our Beijing facility and our core business in Beijing. Lotus has a well-established nationwide sales and distribution network, and strong product development capabilities. With the completion of our new headquarters, we believe we are well positioned with respect to the ongoing consolidation of the Chinese pharmaceutical industry."

    Second Quarter Results of OperationsRevenuesRevenues for the quarter ended June 30, 2011 were $18.7 million, compared to $18.9 million in the second quarter of 2010. The decrease of 1.1%, or $0.2 million, was primarily due to decreased sales from the Company's wholesale distribution channel, partially offset by the growth in its retail sales segment. Wholesale revenue decreased 5.6% year-over-year to $14.6 million, or 78% of total revenues. Retail revenues increased 19.2% year-over-year to $4.1 million, or 22% of total revenues. The growth in the retail segment was mainly due to an increase in revenue from our direct sales to other Over-the-Counter drug stores in Beijing.

    Gross ProfitGross profit for the second quarter ended June 30, 2011 was $4.9 million or 26.1% of total net revenues, as compared to $9.8 million or 51.8% of total net revenues for the quarter ended June 30, 2010.  The decrease of 50.1%, or $4.9 million, was primarily attributable to lower product prices in 2011 compared to 2010.

    Income from OperationsOperating income amounted to $1.8 million for the quarter ended June 30, 2011 as compared to operating income of $6.4 million for the second quarter of 2010. The decrease of 71.8%, or $4.6 million, was due largely to decreased gross profit.

    Net IncomeNet income for the quarter ended June 30, 2011 was $1.8 million as compared to $6.3 million for the quarter ended June 30, 2010, due to the reasons set forth above. Earnings per diluted share were $0.06 for the quarter, compared with diluted EPS of $0.24 for the second quarter of 2010.

    Liquidity and Capital ResourcesAs of June 30, 2011, the Company's current assets were $7.2 million and current liabilities were $10.9 million. Cash and cash equivalents totaled $0.9 million as of June 30, 2011. The Company's shareholders' equity at June 30, 2011 was $ 97.2 million. The Company generated $6.7 million in cash from operating activities in the first half of fiscal 2011, compared to $8.9 million in the same period of 2010. The Company used $7.1 million cash for investing activities during the first half of fiscal 2011, compared to $11.8 million in the same period of 2010.

    Recent Business Highlights

  • The Company continues to make progress in the construction of its headquarters building in Chaoyang District, Beijing. Currently the project is in its final interior furnishing stage. Once completed, this state-of-the-art building will host the Company's GMP manufacturing facility, a storage warehouse, an R&D center, a sales and marketing center, and administrative offices, as well as employee apartments. The Company reiterates the plan to complete and move into the facility by the end of the year.

  • Business Outlook for 2011Management expects that 2011 will be a transitional year for Lotus Pharmaceuticals, as the Company will be completing and moving into its new headquarters and shifting its focus to the wholesale business in Beijing and the surrounding areas. After the completion of the headquarters, the Company expects growth will resume, primarily driven by the wholesale business in Beijing starting in 2012.

    Conference Call and WebcastManagement will host a conference call to discuss these financial results on Wednesday, August 17, 2011 at 10:00 a.m. EDT (7:00 a.m. PDT).

    To participate in the call, please dial (877) 941-4774, or (480) 629-9760 for international calls, approximately 10 minutes prior to the scheduled start time.

    A replay of the call will be available for two weeks from 1:00 p.m. EDT on August 17, 2011, until 11:59 p.m. EDT on August 31, 2011. The number for the replay is (877) 870-5176, or (858) 384-5517 for international calls; the passcode for the replay is 4466487.

    About Lotus Pharmaceuticals, Inc. Lotus Pharmaceuticals, Inc. is a profitable developer and producer of drugs and a licensed national seller of pharmaceutical items in the People's Republic of China (PRC). Lotus operates its business through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development is focused on the treatment of cerebro-cardiovascular diseases, asthma and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.

    Information Regarding Forward-Looking StatementsExcept for historical information contained herein, the statements in this press release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause our actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product demand, market competition, and risks inherent in our operations. These and other risks are described in our filings with the U.S. Securities and Exchange Commission.Contacts:Xing Shen, Ph.D.VP of Corporate DevelopmentLotus Pharmaceuticals, Inc.Ph: 415-690-7688Email: shen@lotuspharma.comWeb: http://www.lotuspharma.comLOTUS PHARMACEUTICALS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(UNAUDITED)June 30, December 31,2011 2010ASSETSCURRENT ASSETS:Cash

    $886,445$1,339,972Accounts receivable


    895,176634,583Prepaid expenses and other current assets

    539,847593,759Total Current Assets

    7,199,2134,541,464PROPERTY AND EQUIPMENT, net

    47,248,48439,337,935OTHER ASSETSLand use right held for development or sale

    29,905,39629,236,891Deposits and Installments on intangible assets

    9,746,2879,528,419Land use rights, net

    13,066,53012,932,421Other intangible assets, net

    7,327,6347,607,485Total Assets


    $20,111$37,829Other payables and accrued liabilities

    802,4313,441,466Taxes payable

    7,321,7832,024,565Unearned revenue

    534,231504,442Dividend payable

    3,308-Due to related parties

    2,186,5962,042,376Total Current Liabilities

    10,868,4608,050,678LONG-TERM LIABILITIES:Due to related parties

    1,014,586869,067Notes payable - related parties

    5,361,6845,241,829Total Liabilities

    17,244,73014,161,574COMMITMENTS AND CONTIGENCIESSTOCKHOLDERS' EQUITY:Preferred stock ($.001 par value; 10,000,000 shares authorized;9,824 and 607,107 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively)

    620607Common stock ($.001 par value; 100,000,000 shares authorized;27,747,131 and 26,763,485  shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively)

    27,74726,763Additional paid-in capital

    23,785,66521,679,147Retained earnings

    57,919,58453,925,101Statutory reserves

    6,240,2026,240,202Accumulated other comprehensive income

    9,274,9967,151,221Total stockholders' Equity

    97,248,81489,023,041Total Liabilities and Stockholders' Equity

    $114,493,544$103,184,615LOTUS PHARMACEUTICALS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME(UNAUDITED)For the Three Months EndedFor the Six Months EndedJune 30,June 30,2011201020112010NET REVENUES:  Wholesale$14,590,654$15,464,138$23,309,677$26,962,224  Retail4,103,7833,442,3558,302,0006,694,747Total Net Revenues18,694,43718,906,49331,611,67733,656,971COST OF REVENUES:  Wholesale10,679,4316,613,65014,431,94010,526,848  Retail3,127,9622,492,1016,139,7594,822,532Total Cost of Revenues13,807,3939,105,75120,571,69915,349,380GROSS PROFIT4,887,0449,800,74211,039,97818,307,591OPERATING EXPENSES:Selling expenses737,1652,375,1592,140,7114,544,112Research and development expenses691,793-1,419,224-General and administrative expenses1,669,8871,075,3483,442,1862,097,205Total Operating Expenses3,098,8453,450,5077,002,1216,641,317INCOME FROM OPERATIONS1,788,1996,350,2354,037,85711,666,274OTHER INCOME (EXPENSE):Debt issuance costs---(52,226)Other income47,100198,50893,614396,942Interest income8769061,5662,186Interest expense(62,404)(59,428)(124,033)(491,830)Total Other Income (Expense)(14,428)139,986(28,853)(144,928)INCOME BEFORE INCOME TAXES1,773,7716,490,2214,009,00411,521,346INCOME TAXES-167,959149270,166NET INCOME1,773,7716,322,2624,008,85511,251,180OTHER COMPREHENSIVE INCOME:Foreign currency translation gain1,546,706323,2702,123,775334,198COMPREHENSIVE INCOME3,320,4776,645,532$6,132,630$11,585,378NET INCOME PER COMMON SHARE:Basic$
    .24$   0.14$

    $4,008,855$11,251,180Adjustments to reconcile net income from operations to net cashprovided by operating activities:Depreciation

    211,29712,920Amortization of intangible assets

    607,476876,619Amortization of deferred debt issuance costs

    -52,226Amortization of discount on convertible redeemable preferred stock

    -151,553Interest expense attributable to beneficial conversion feature of preferred shares

    -184,660Common shares issued for service

    708,350120,450Common shares issued for compensation

    1,388,101109,500Changes in assets and liabilities:Accounts receivable


    (242,920)(637,828)Prepaid expenses and other current assets

    66,602354,472Accounts payable

    (18,344)64,675Other payables and accrued liabilities

    (2,679,315)(630,615)Taxes payable

    5,183,422592,024Unearned revenue

    18,020(519,697)Due to related parties


    6,654,1898,908,338CASH FLOWS USED IN INVESTING ACTIVITIES:Purchase of property and equipment

    (7,132,250)(11,780,895)NET CASH USED IN INVESTING ACTIVITIES



    24,5345,541NET DECREASE IN CASH

    (453,527)(2,867,016)CASH  - beginning of period

    1,339,9723,945,740CASH - end of period

    $886,445$1,078,724SUPPLEMENTAL DISCLOSURE OF CASH FLOW  INFORMATION:Cash paid for:Interest

    -Income taxes

    $3,672$3,746Non-cash investing and financing activities:Common stock issued for services

    -$397,050Common stock issued for conversion of convertible redeemable preferred stock

    -$4,048,200Convertible redeemable preferred stock reclassified to permanent equity

    -$595,233Convertible preferred stock issued for dividend payable


    SOURCE Lotus Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
    2. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
    3. Lotus Pharmaceuticals, Inc. Reports Third-Quarter 2009 Results
    4. Lotus Pharmaceuticals, Inc. to Exhibit at the 62nd PHARMCHINA
    5. Lotus Pharmaceuticals, Inc. Strengthens Beijing Presence with Direct Sales to Drug Stores
    6. Lotus Pharmaceuticals Reports Groundbreaking Ceremony
    7. Lotus Pharmaceuticals to Exhibit at the 63rd PHARMCHINA
    8. Lotus Pharmaceuticals Laevo-Bambuterol Received SFDA Approval to Commence Clinical Trials
    9. Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results
    10. Pink Lotus Breast Center to Integrate Electronic Brachytherapy Cancer Treatment Platform
    11. Lotus Pharmaceuticals to Present at Global Hunter Securities 2010 China Conference
    Post Your Comments:
    (Date:10/13/2015)... Ga. , Oct. 13, 2015  EndoChoice Holdings, ... its third quarter 2015 financial results on Thursday, November ... . --> . ... on Thursday, November 5, 2015 at 9:00 a.m. ET ... 328-5344 for domestic callers and (412) 317-5469 for international ...
    (Date:10/13/2015)... --> --> ... from the Asthma and COPD Therapies market? Which areas are ... brand new report shows you potential revenues to 2025, assessing ... provides 260 tables, charts, and graphs. Discover the most lucrative ... new study lets you assess forecasted sales at overall world ...
    (Date:10/13/2015)... 13, 2015  XiMo AG ( Lucerne ... Inc. ( Milpitas, California ) announced today ... chemistry. The importance of metathesis chemistry was highlighted by ... of this application. This industrially-relevant application has been utilized ... pharmaceuticals, specialty chemicals, and polymers. Georg Fráter ...
    Breaking Medicine Technology:
    (Date:10/13/2015)... ... October 13, 2015 , ... PhyMed Healthcare ... today announced its partnership with WPC Healthcare , a provider of predictive ... organizes the data into an aggregated data repository necessary to perform reporting and ...
    (Date:10/13/2015)... ... 13, 2015 , ... Altec Products, Inc., the leader in ... Dynamics AXUG, GPUG and NAVUG Summits to take place the week of October ... user conferences designed and led by users to provide attendees with a unique ...
    (Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... through a unique private messaging application, announced today a significant contract that will ... five years. Independence plans to build on the growing success of its Relay ...
    (Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... A child ... that’s why SmileCareClub , the leading remote invisible aligner system, has joined with ... would otherwise go without it. For each aligner treatment plan purchased, SmileCareClub will donate ...
    (Date:10/13/2015)... ... October 13, 2015 , ... ... product that targets the unique health needs of new moms. Postnatal Omega-3, ... Association ( ), utilizes Nordic Naturals’ exclusive, new, ultra-concentrated omega-3 oil. ...
    Breaking Medicine News(10 mins):